health pharma news today obesity drugs glp-1 today The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Scam weight-loss drops marketed to

Description

Otero-Martinez, A

23 Clinical trials also indicated that GLP-1 RA treatment for obese patients presented superior weight loss efficacy compared to other anti-obesity medications

People who took Zepbound and suffered from NAION (an eye stroke) may be entitled to legal compensation

Private healthcare expansion and international pharmacy channels are improving treatment accessibility despite limited public reimbursement coverage

The researchers found that patients who gained or maintained weight while on a GLP-1 receptor agonist were more likely to lose weight after switching to phentermine, with a median weight loss of around 3% in the year after GLP-1 discontinuation